SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Why the future of marijuana legalization remains hazy despite high public support 
The four types of dementia most people don’t know exist 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Drugmaker Merck has partnered with Daiichi Sankyo, under which it will pay $5.5 billion to develop three candidate cancer drugs jointly. This deal could be worth up to $22 billion for Daiichi Sankyo, depending on the success of the therapies.
Shares of Daiichi Sankyo soared by 14.4% in Tokyo, marking their largest gain in over a year. Merck also saw a rise of 1.6% in morning trading.
Ambitious Revenue Target for Daiichi Sankyo's Oncology Business
According to Reuters, Daiichi Sankyo has set a revenue target of at least 900 billion yen ($6 billion) for its oncology business by the fiscal year ending March 31, 2026. This would represent an impressive five-fold increase over three years.
Investopedia noted that the three-drug candidates to be developed with Merck fall into the antibody-drug conjugates (ADC) class, with various stages of clinical development for treating multiple solid cancer tumors. Unlike conventional chemotherapy, ADCs are designed to target cancer cells, minimizing damage to healthy cells specifically.
"One of the changes in the external environment is intensifying competition in ADC development," Daiichi Sankyo CEO Sunao Manabe said, describing the company's decision to seek a partner.
Promising Commercial Revenue Potential
The drug candidates - patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan - hold significant worldwide commercial revenue potential for both companies by the mid-2030s, according to Merck and Daiichi Sankyo.
Under the agreement, Merck and Daiichi Sankyo will jointly develop and potentially commercialize the drug candidates globally, except in Japan, where Daiichi Sankyo will retain exclusive rights. Daiichi Sankyo will be responsible for manufacturing and supply.
Merck Gains Access to Daiichi Sankyo's Expertise in the ADC Space
The partnership allows Merck to tap into Daiichi Sankyo's leadership status in the ADC field. Analysts believe this collaboration will strengthen Merck's cancer drug portfolio, particularly as its top-selling Keytruda faces patent expiration at the end of the decade.
In return for the collaboration, Merck will make an upfront payment of $4 billion to Daiichi Sankyo, followed by $1.5 billion in continuation payments over the next two years. Additionally, Merck may pay up to $16.5 billion based on future sales milestones, amounting to $5.5 billion for each product.
Daiichi Sankyo has six ADC candidates in its pipeline, including two jointly developed with AstraZeneca. However, this week's disappointing data abstract on the late-stage trial of datopotamab deruxtecan, developed with AstraZeneca, has impacted analysts' expectations.
Photo: Merck Media
